跳至主要内容
临床试验/NCT00318799
NCT00318799已完成2 期

A Single-centre, Open-label, Crossover, Controlled, Randomized Study to Investigate the Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters in 30 Healthy Female Volunteers Over 3 Treatment Cycles

Bayer1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2006年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Bayer
入组人数
29
试验地点
1
主要终点
Intraindividual absolute changes from Baseline in the Parameters of thrombin and fibrin turnover

研究概览

简要总结

The aim of this study is to evaluate the impact of SH T00658ID (EV/DNG tablet) on hemostatic parameters in comparison to a reference oral contraceptive (OC) (SH D01155E) in a crossover design.

详细描述

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Healthy female volunteers

排除标准

  • Pregnancy or lactation
  • Any condition that might interfere with the outcome as all contraindications for OC use.

研究组 & 干预措施

Arm 1

Experimental

干预措施: EV/DNG (Qlaira, BAY86-5027, SH T00658ID) (Drug)

Arm 2

Active Comparator

干预措施: SH D01155E (Drug)

结局指标

主要结局

Intraindividual absolute changes from Baseline in the Parameters of thrombin and fibrin turnover

时间窗: Baseline, Cycle 3 of each treatment period

次要结局

  • Intraindividual absolute changes from Baseline in Pro- and anti-coagulatory parameters and the parameter of thrombin and fibrin turnover (activation marker): Prothrombin (Factor II).(Baseline, Cycle 3 of each treatment period)
  • Adverse events(2 treatment periods (3 cycles each), 2 cycles whash out-period and 14 days follow-up period)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Impact of SH T00658ID as Compared to a Monophasic... | 临床试验